Real-World Healthcare Resource Utilization (HCRU) and Costs Among Patients with Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT) with Covid-19 in a Commercially Insured or Medicare Advantage (MA) Population

Document Type

Conference Proceeding

Publication Date

6-1-2023

Publication Title

Am J Transplant

Abstract

Purpose: Estimate the incidence of COVID-19 and long COVID-19 syndrome and evaluate HCRU and costs associated with COVID-19 among HSCT and SOT patients. Methods: HSCT and SOT patients were retrospectively identified from the Health-Core Integrated Research Database between 4/1/2018 and 3/31/2022 (study end date). The first transplant date or 4/1/2020 was set as the index date, whichever came last. Patients were enrolled in a commercial or MA insurance plan for 1 year prior to index and followed until disenrollment, study end date or death. COVID-19 was identified through diagnosis codes on medical claims and outpatient laboratory results. Incidence rates (IRs) for COVID-19 and long COVID-19 were calculated. Hospitalized patients were classified as severe (intensive care unit stay with noninvasive high flow oxygen or invasive respiratory/cardiovascular support or discharge status of expired) or moderate (all other hospitalizations); length of stay (LOS) and inpatient costs were calculated. All-cause HCRU and costs were calculated for the 30 days pre/post-COVID-19. Results: In total, 28,698 HSCT or SOT patients were identified (mean age: 53 years; 58% male) and followed for 17 months on average. During follow up, 16% of HSCT/SOT patients developed COVID-19; the IRs of COVID-19 and long COVID-19 are shown (Figure). Total mean costs among these patients increased from $9,144 pre-COVID-19 to $30,181 post-COVID-19. Of the 33% of HSCT or SOT patients hospitalized for COVID-19, 46% were severe with a mean LOS of 20 days and total cost of $121,609, while 54% were moderate with a mean LOS of 11 days and total cost of $34,210. Conclusions: Patients with HSCT or SOT have high IRs of COVID-19 with substantial associated costs. These findings show high burden of COVID-19 and unmet need, highlighting opportunities to improve COVID-19 prevention and care for this population. CITATION INFORMATION: Pizzicato L., Willey V., Pollack M., Wenziger C., Glasser L., Teng C., Hirpara S., Dube C., Verduzco-Gutierrez M., Cunningham D. Real-World Healthcare Resource Utilization (HCRU) and Costs Among Patients with Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT) with Covid-19 in a Commercially Insured or Medicare Advantage (MA) Population AJT, Volume 23, Issue 6, Supplement 1. DISCLOSURES: [Figure presented]

Medical Subject Headings

Infectious Diseases

PubMed ID

Not assigned.

Volume

23

Issue

6

First Page

S674

Find It @ Sladen

Share

COinS